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ment. Undulated areas of the retinal side presented stiffer 
than the vitreal side of the ILM. Topographical mapping of 
both the vitreal and retinal side of the ILM showed no appar-
ent alteration of the morphology in ocriplasmin-treated eyes 
compared to untreated eyes. Staining with BB resulted in an 
increase of tissue stiffness.  Conclusions: Intravitreal injec-
tion of ocriplasmin does not change biomechanical proper-
ties of the human ILM. There is no evidence of a potential 
enzymatic effect of ocriplasmin interfering with the stiffness 
of this basement membrane.  © 2016 S. Karger AG, Basel 
 Introduction 
 Ocriplasmin (Jetrea ® , ThromboGenics, Leuven, Bel-
gium) is an unspecific and recombinant truncated form 
of the human serine protease plasmin that exerts proteo-
lytic activity on laminin and fibronectin, both major com-
ponents of the vitreoretinal interface  [1] . Pharmacologic 
vitreolysis with ocriplasmin was recently approved for the 
treatment of patients with symptomatic vitreomacular 
adhesion and vitreomacular traction (VMT), including 
when associated with full-thickness macular holes  ≤ 400 
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 Abstract 
 Purpose: To assess the stiffness of the human internal limit-
ing membrane (ILM) and evaluate potential changes of me-
chanical properties following intravitreal ocriplasmin injec-
tion for vitreomacular traction.  Methods: This is an interven-
tional comparative case series of 12 surgically excised ILM 
specimens consecutively obtained from 9 eyes of 9 patients 
after unsuccessful pharmacologic vitreolysis with ocriplas-
min. During the same time period, 16 specimens from 13 
other eyes without ocriplasmin treatment were harvested 
during vitrectomy and served as controls. All patients pre-
sented with macular holes or vitreomacular traction and un-
derwent vitrectomy with ILM peeling either with or without 
brilliant blue (BB) staining. All specimens were analyzed us-
ing atomic force microscopy with scan regions of 25 × 25 μm. 
In all specimens, both the retinal side and vitreal side of the 
ILM were analyzed.  Results: Atomic force microscopy re-
vealed no significant differences in elasticity of ILM speci-
mens removed from eyes with or without ocriplasmin treat-
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μm in diameter  [2, 3] . Release of VMT can be achieved by 
pharmacologic vitreolysis in up to 70% of cases after a 
single intravitreal injection of ocriplasmin into the vitre-
ous cavity (0.125 mg/0.1 ml), as confirmed by subgroup 
analyses of eyes with VMT  [4, 5] .
 Compared to pars plana vitrectomy with peeling of the 
internal limiting membrane (ILM), which was the only 
treatment option until recently, intravitreal ocriplasmin 
injection provides a generally well-tolerated therapeutic 
intervention for patients with VMT  [6, 7] . There are nu-
merous potential advantages of pharmacologic vitreolysis 
over surgical vitrectomy, such as avoidance of surgical 
risks, faster visual rehabilitation, and induction of a com-
plete posterior vitreous detachment without remnants of 
vitreous cortex collagen on the ILM.
 However, some concerns were raised regarding the 
safety profile of ocriplasmin. A more detailed analysis of 
safety data from phase 2 and 3 trials as well as clinical case 
reports and small case series revealed acute panretinal 
structural and functional abnormalities after ocriplasmin 
treatment that do not seem to be related to the induction 
of complete posterior vitreous detachment alone. One 
may hypothesize that under the light of this information, 
ocriplasmin may somehow affect deeper retinal cellular 
structures or components relevant for retinal integrity. In 
this case, ocriplasmin would have to penetrate the ILM. 
Given the enzymatic properties of ocriplasmin, one may 
assume that ocriplasmin also affects known ILM compo-
nents such as laminin and fibronectin. This effect would 
likely have an impact on the biomechanical properties of 
the ILM, which is a very rigid tissue whose biomechanical 
rigidity or stiffness resembles articular cartilage.
 Atomic force microscopy (AFM) is a well-established 
technique to measure tissue rigidity of basement mem-
branes such as the ILM on a nanoscale level  [8–11] . In the 
present experimental study, we used this technique to 
quantify potential changes of biomechanical properties of 
the ILM following ocriplasmin treatment for tractional 
maculopathies such as macular holes or VMT syndrome.
 Materials and Methods 
 This is an interventional comparative case series of 12 surgi-
cally excised ILM specimens consecutively obtained from 9 eyes of 
9 patients after unsuccessful pharmacologic vitreolysis with ocri-
plasmin who underwent vitrectomy with ILM peeling at the De-
partment of Ophthalmology, Ludwig Maximilian University, and 
at the Herzog Carl Theodor Eye Hospital, Munich between May 
2014 and January 2015. The Institutional Review Board and the 
Ethics Committee of the Ludwig Maximilian University, Munich 
approved the retrospective review of the patients’ data as well as 
the preparation and analysis of the patients’ specimens (No. 471-
14). This study was conducted according to the tenets of the Dec-
laration of Helsinki.
 Six eyes showed persistent macular holes and 3 eyes presented 
with persistent symptomatic VMT as confirmed by high-resolu-
tion optical coherence tomography. Five of 6 eyes with macular 
holes were seen with resolution of VMT and progression of the 
macular hole diameter after ocriplasmin injection. Macular sur-
gery followed ocriplasmin injection after a mean period of 4.1 
months (range 1–10 months). Eyes with macular holes underwent 
surgery after a mean period of 2.3 months (range 1–3 months), 
which was significantly earlier than eyes with VMT. Pharmaco-
logic vitreolysis with ocriplasmin was applied according to the 
guidelines of the German Ophthalmological Society, the Retina 
Society and the Professional Association of German Ophthalmol-
ogists for therapeutic intravitreal application of ocriplasmin.
 During the same time period, 16 specimens from 13 other eyes 
without ocriplasmin treatment were harvested during vitrectomy 
and served as controls. In this control group, we included 4 speci-
mens of 4 eyes with idiopathic macular holes and 12 specimens 
from 9 eyes with VMT.
 In 3 eyes with ocriplasmin treatment, 2 specimens were har-
vested during vitrectomy, respectively. In these cases, the first 
specimen was removed without intravitreal staining of the ILM 
during surgery, the second specimen was removed with usage of 
vital dye brilliant blue (BB). Similarly, in 3 eyes of the control group 
without ocriplasmin treatment, 2 specimens per eye were removed 
during vitrectomy as illustrated above.
 Surgical Procedure and Specimen Removal 
 The surgical technique consisted of a 23-gauge 3-port pars pla-
na vitrectomy with peeling of the ILM. All patients were operated 
by 3 experienced surgeons. Vitrectomy was performed as follows: 
before opening the infusion line, the status of the posterior hyaloid 
was determined using a plano-concave contact lens. If the vitreous 
was attached or partially attached to the retina, posterior vitreous 
detachment was induced by suction with the vitrectomy probe 
over the optic disc or in the midperiphery. The posterior hyaloid 
was detached from the retina and excised up to the periphery.
 To improve the precision of ILM peeling and to avoid incom-
plete removal, brilliant blue G (BBG; 0.2 ml, brilliant peel; Geuder, 
Heidelberg, Germany) was used to visualize the ILM in 7 eyes with 
previous ocriplasmin treatment and in 8 eyes without ocriplasmin 
treatment. All other eyes were operated without intraoperative 
staining of the ILM. In a subgroup of eyes with BB staining, the 
first ILM specimen was removed without BBG, and the second 
specimen was removed with usage of BB. In all other eyes, only 1 
specimen was harvested. If applied, the dye solution was injected 
onto the vitreomacular interface and immediately washed out. No 
other dye was applied. Peeling of the ILM was performed using 
end-gripping Eckardt forceps. If necessary, removal of the ILM 
was performed en bloc with epiretinal tissue.
 Surgery was completed by checking the retinal periphery for 
breaks. In eyes with small macular holes, the vitreous cavity was 
perfused with a mixture of 15% C2F6 following a fluid-air ex-
change. In eyes with persistent vitreomacular adhesion, balanced 
salt solution was left in the vitreous cavity at the end of the proce-
dure. The removed ILM specimens were harvested and immedi-
ately placed onto glass slides without fixation.
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 Atomic Force Microscopy 
 For AFM analysis, a NanoWizard ® 3 AFM (JPK-Instruments, 
Berlin, Germany) mounted on an inverted optical microscope 
(Carl Zeiss, Jena, Germany) was used, which allows the selection 
of the exact scanning area by visualizing the ILM with a 10× objec-
tive ( fig. 1 a). Specimens were mounted on microscopy slides and 
subjected to AFM measurements to outline topography and elas-
ticity. For each specimen, measurement areas were selected from 
the optical image where the membrane was clearly seen blank 
without epiretinal cells or collagen ( fig. 1 a). The typical morphol-
ogy of the rough retinal and rather smooth vitreal side was also 
outlined by AFM height images and laminin staining ( fig. 1 b, c). 
Throughout all experiments, the AFM was operated in QI mode, 
a force spectroscopy-based imaging mode that allows for simulta-
neous measurements of topography and elasticity of the speci-
mens.
 Pyramidal-shaped D tips of Si 3 N 4 cantilevers (MLCT, Bruker, 
Mannheim, Germany) with a nominal spring constant of 0.03 N/m 
were used. The spring constant k was determined using the ther-
mal noise method  [12] . Samples were measured under physiolog-
ical conditions at 37  °  C in PBS. For overview pictures, 25 × 50 μm 
wide scanning areas were chosen with a resolution of 512 × 256 
pixels ( fig. 1 a,  * ). For elasticity maps, 25 × 25 μm wide scanning 
areas (3 different areas/side) where chosen from the optical image 
and resolution was set to 64 × 64 pixels ( fig. 1 a, #). For each pixel, 
information on height (for generation of topography maps) and 
elasticity (for calculation of the Young’s modulus, YM) were re-
corded. In total, 3 areas with 4,096 measurements each were ob-
tained for each specimen. A Z-length of 2,000 nm, an extending 
and retracting speed of 100 μm/s (overview maps) or 10 μm/s (elas-
ticity maps), an additional retract of 200 nm and a relative set point 
of 0.2 nN was applied to avoid sample alterations due to mechani-
cal strain. For determination of YM, the JPK analysis software was 
applied, which calculates YM using the Bilodeau formula for py-
ramidal indenter of the Hertz model  [13, 14] .
 Due to simultaneous delineation of topography and elasticity, 
sample orientation with differentiation between the vitreal and the 
retinal side of the ILM could be specified during measurements. 
Additional tests to confirm orientation of the specimens were per-
formed after AFM measurements. All specimens were fixed with 
2% paraformaldehyde solution and processed for indirect immu-
nostaining with mouse anti-human laminin antibody (clone 4C7; 
Dako, Hamburg, Germany) and a Cy3-coupled goat anti-mouse 
(Dianova, Hamburg, Germany) secondary antibody. Image cap-
turing was performed using an SP5 confocal microscope equipped 
with a Plan Apo 20× NA 0.7 and a Plan Apo 63× NA 1.4 objective 
(both Leica, Mannheim, Germany;  fig. 1 c).
 Data Analysis and Statistics 
 All surgically excised specimens were processed blinded and 
analyzed by 2 investigators independently according to 4 groups 
as follows: (1) specimens after ocriplasmin treatment removed 
with intravitreal usage of BB; (2) specimens after ocriplasmin 
treatment removed without intravitreal staining of the ILM; (3) 
specimens without ocriplasmin treatment removed with intravit-
real usage of BB, and (4) specimens without ocriplasmin treatment 
removed without intravitreal staining of the ILM.
 Images and YM fit were processed using the JPK data process-
ing software. Further analysis was done using Adobe Photoshop 
CS5. Data values were compared using one-way ANOVA with 
Kruskal-Wallis and Tukey’s multiple comparison test in Prism 
(Graphpad Software, La Jolla, Calif., USA). Statistical significance 
was presumed for p < 0.05. Data are displayed as mean ± standard 
error of the mean.
 Results 
 AFM revealed no significant differences in elasticity of 
ILM specimens removed from eyes with or without ocri-
plasmin treatment. Specimens removed from eyes with 
ocriplasmin treatment but without staining with BB dis-
played a slightly but not significantly increased YM of 
34.18 ± 8.47 kPa on the vitreal and 148.11 ± 27.29 kPa on 
the retinal side of the ILM. In contrast, in untreated con-
trol group eyes, the ILM demonstrated a YM of 16.29 ± 
3.34 kPa on the vitreal and 122.76 ± 26.64 kPa on the 
retinal side ( fig. 2 a, YM). According to topography and 
elasticity measurements, undulated areas of the retinal 
side presented stiffer ( fig. 2 a, YM, white arrows). Topo-
graphical mapping of both the vitreal and retinal side of 
the ILM showed no apparent alteration of the morphol-
ogy in ocriplasmin-treated eyes compared to eyes without 
ocriplasmin injection before vitrectomy ( fig.  2 a). Simi-
larly, no alterations in topography were found in the com-
parison of unstained ILM peeling and ILM peeling with 
BB.
 When comparing ILM specimens removed with or 
without intravitreal application of BB, there was a differ-
ence in YM between specimens removed with or without 
BB. The intravitreal application of BB for easy and safe 
ILM peeling resulted in an increased YM, which was es-
pecially prominent on the vitreal side ( fig. 2 b). In the ocri-
plasmin-untreated eyes, the use of BB resulted in a sig-
nificant increase in YM of 16.29 ± 3.34 kPa on the vitreal 
side and 122.76 ± 26.64 kPa on the retinal side. In un-
stained eyes, the YM measured 68.17 ± 18.74 kPa on the 
vitreal side and 152.1 ± 17.46 kPa on the retinal side of the 
ILM. In ocriplasmin-treated eyes, the increase after BB 
staining was less pronounced with a YM of 34.18 ± 8.47 
 Fig. 1.  a Optical image of peeled ILM. The ILM is partially flipped 
over to expose the vitreal and retinal side. The retinal side is marked 
in green, the vitreal side in blue (upper picture). Scanning areas 
(green/blue rectangles) were first selected for identification of the 
respective side of the ILM (50 × 25 μm, 512 × 256 pixels,  * ) and 
subsequently for topography and elasticity measurements on both 
sides (25 × 25 μm, 64 × 64 pixels, #).  b Rough and undulated reti-
nal and smooth vitreal ILM side.  c ILM stained for laminin for 
fluorescence microscopy. Again, rough retinal and smooth vitreal 
sides are clearly distinguishable. 
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kPa on the vitreal side and 148.11 ± 27.29 kPa on the ret-
inal side in unstained ILM, compared to a YM of 49.42 ± 
10.89 kPa on the vitreal side and 166.65 ± 31.49 kPa on 
the retinal side of the ILM in eyes with BB-assisted ILM 
peeling ( fig. 2 a, b).
 To study the effect of BB-assisted ILM peeling in eyes 
with ocriplasmin, we investigated specimens from 3 eyes 
who underwent vitrectomy with peeling of a first un-
stained ILM specimen followed by application of BB with 
peeling of a second stained ILM specimen. Topography 
and elasticity analysis were performed in both specimens 
as illustrated above. YM before staining was set to 1.0 
( fig. 3 a). Topography maps confirm that morphology of 
the ILM is not altered by BB application. Furthermore, a 
slight but not significant increase of elasticity was evident 
comparing both sides before and after BB application in 
these eyes ( fig. 3 b).
 Discussion 
 Since laminin constitutes a family of glycoproteins 
that are integral parts of the structural scaffolding of base-
ment membranes  [15–18] and ocriplasmin exerts proteo-
lytic activity on laminin, the purpose of this study was to 
investigate the enzymatic effect of ocriplasmin on biome-
chanical properties of the ILM. We included ILM speci-
mens removed from eyes that underwent vitrectomy with 
ILM peeling with and without ILM staining using BBG 
after unsuccessful ocriplasmin treatment and compared 
these to specimens removed from eyes that had no ocri-
plasmin injection prior to surgery.
 The present study is in line with and confirms the re-
sult of our previous report using AFM measurements fol-
lowing ILM staining using vital dyes  [10] . In accordance 
with our previous investigation, we confirmed a stiffen-
ing effect of the ILM following BB application, which 
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could not be seen in unstained ILM specimens. In addi-
tion, we observed a more pronounced stiffening effect of 
the ILM following the use of indocyanine green com-
pared to BBG, especially after illumination of the stained 
specimen. This may be related to the fact that indocya-
nine green has photosensitizing properties which may in-
crease this effect. Furthermore, we observed differences 
in tissue elasticity when analyzing the retinal and vitreal 
surface of the ILM both in unstained and stained speci-
mens, with the retinal surface of the ILM being stiffer than 
the vitreal side. The confirmation of our previous results 
assured that the AFM is a reliable technique with repro-
ducible results. Based on our findings, we are confident 
that a potential enzymatic effect of ocriplasmin on the 
ILM interfering with the stiffness of the tissue would have 
been detectable by AFM, if present.
 Ocriplasmin is currently used and approved for the 
treatment of small macular holes and VMT smaller than 
1,500 μm by intravitreal injection  [2] . Applied intravit-
really, the enzyme has been shown to induce a posterior 
detachment and liquefaction of the vitreous. Clinical re-
ports and small case series raised concern on potential 
side effects of the enzyme. These studies reported on clin-
ical symptoms and findings including varying degrees of 
retinal dysfunction, such as visual acuity loss, dyschro-
matopsia, nyctalopia, visual field constriction, outer ret-
inal signal abnormalities or defects on spectral domain 
optical coherence tomography, macular hole enlarge-
a
b
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ment, macular detachment with subretinal fluid accu-
mulation, and electroretinography changes  [6, 7, 12–14, 
19–25] .
 The ILM of the retina is a multi-laminar structure 
mainly composed of type IV collagen, laminin and fibro-
nectin and essentially represents the basement membrane 
of Müller cells. Under higher magnification, it typically 
reveals a smooth vitreal surface and a rough surface which 
is oriented towards the retina. This distinct morphologi-
cal appearance helps to identify the respective surface 
during microscopy studies as performed herein. Al-
though it was experimentally shown that ocriplasmin 
seems not to affect the structural aspect of the vitreal ILM 
surface using electron microscopy  [1] , we do not have any 
information on potential alterations of the biomechanical 
properties of the ILM following the contact of the retinal 
surface with ocriplasmin, which may very well not be de-
tectable using microscopy. Such alterations may be the 
result of the known enzymatic properties of ocriplasmin, 
with laminin and fibronectin being important enzymatic 
targets. Both laminin and fibronectin are also relevant 
components of the ILM. The proteolysis of these struc-
tures may allow the drug to even penetrate the ILM and 
reach the outer layers of the neurosensory retina, thereby 
cleaving laminin throughout the retinal layers  [12–14] . 
Of note, laminin was not only reported to be a component 
of the ILM as mentioned, but also of the outer plexiform 
layer, the external limiting membrane, and the interpho-
toreceptor matrix  [26–28] . Although cleavage of more 
than one protein may be responsible for the various man-
ifestations of ocriplasmin-induced retinal dysfunction, it 
was hypothesized that degradation of intraretinal laminin 
plays an important role in ocriplasmin-associated side ef-
fects  [12–14] .
 However, the present investigation has some limita-
tions. Of note, AFM provides measurements of the tissue 
surface elasticity, which does only indirectly provide in-
formation about the deeper aspects of the ILM. Neverthe-
less, we did not see any changes of the stiffness of the ILM 
following ocriplasmin exposure and it seems very reason-
able to assume that an affection of deeper ILM layers is 
unlikely in the presence of this result. More importantly, 
AFM measurements as performed herein do not repre-
sent direct measurements of the changes of the tensile 
strength of the ILM. Nevertheless, as the ILM represents 
an irregularly structured meshwork of various fibers, one 
may transfer our findings and conclude that a change of 
the tensile properties is very unlikely to occur.
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